| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 in patients with myasthenia gravis
Medical Neurology Branch (Drs. Dalakas, Rose, Paul, and Engel), Neuromuscular Diseases Section, National Institute of Neurological & Communicative Disorders & Stroke. Bethesda, MD, and the Department of Biochemistry (Drs. McClure and Goldstein), George Washington University School of Medicine and Health Sciences, Washington, DC.
we studied the interaction of the thymic hormone thymosin 
1 with peripheral blood B and T lymphocytes in patients with myasthenia gravis (MG), using antibodies against thymosin 1 in an immunofluorescence technique. Eleven of 16 patients with symptomatic MG had an increased number of T lymphocytes bearing surface thymosin 1 (T,); 5 patients with asymptomatic disease had normal levels of T1 In six young adults with symptomatic MG who subsequently responded to thymectomy, the number of T1 cells returned to normal 1 month after thymectomy. Because levels of Tl correlated with symptoms and thymosin 1 specifically recruits helper T cells, our findings suggest that T1 may play an immunoregulatory role in the pathogenesis of MG. Determination of T1 levels may prove to be helpful in assessing residual thymic activity after thymectomy.
Address correspondence and reprint requests to Dr. Marinos Dalakas, Building 36, Room 5D06, NIH, NINCDS, Bethesda, MD 20205.
Presented in part at the thirty-third annual meeting of the American Academy of Neurology, Toronto, Canada, May 1981.
Accepted for publication June 18, 1982.
This article has been cited by other articles:
|
|
 |
|
  A. M Pascual, N. Tellez, I. Bosca, J. Mallada, A. Belenguer, I. Abellan, A. P Sempere, P. Fernandez, M. J. Magraner, F. Coret, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required Multiple Sclerosis, November 1, 2009; 15(11): 1303 - 1310. [Abstract] [PDF]
|
|
|
|
|
|
D Otaegui, O Zuriarrain, T Castillo-Trivino, A. Aransay, J Ruiz-Martinez, J Olaskoaga, J. Marti-Masso, and A Lopez de Munain Association between synapsin III gene promoter SNPs and multiple sclerosis in Basque patients Multiple Sclerosis, January 1, 2009; 15(1): 124 - 128. [Abstract] [PDF]
|
|
|
|
|
|
D. Otaegui, A. Saenz, J. Ruiz-Martinez, J. Olaskoaga, and A. Lopez de Munain UCP2 and mitochondrial haplogroups as a multiple sclerosis risk factor Multiple Sclerosis, May 1, 2007; 13(4): 454 - 458. [Abstract] [PDF]
|
|
|
|
|
|
F. Patti, M.P. Amato, M.A. Battaglia, M. Pitaro, P. Russo, C. Solaro, and M. Trojano Caregiver quality of life in multiple sclerosis: a multicentre Italian study Multiple Sclerosis, April 1, 2007; 13(3): 412 - 419. [Abstract] [PDF]
|
|
|
|
|
|
J A Silversides, S V Heggarty, G V McDonnell, S A Hawkins, and C A Graham Influence of C C R5 {delta}32 polymorphism on multiple sclerosis susceptibility and disease course Multiple Sclerosis, April 1, 2004; 10(2): 149 - 152. [Abstract] [PDF]
|
|
|
|
|
|
E L. Hoogervorst, N F Kalkers, L M. van Winsen, B M. Uitdehaag, and C H Polman Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis Multiple Sclerosis, October 1, 2001; 7(5): 335 - 339. [Abstract] [PDF]
|
|
|
|
 |
|
 E.L.J. Hoogervorst, L.M.L. van Winsen, M.J. Eikelenboom, N.F. Kalkers, B.M.J. Uitdehaag, and C.H. Polman Comparisons of patient self-report, neurologic examination, and functional impairment in MS Neurology, April 10, 2001; 56(7): 934 - 937. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
